Home / Peptide legality / New York
Are peptides legal in New York?
New York has no peptide-specific statute, so peptide legality is set by federal FDA compounding and drug law layered on top of New York pharmacy rules, which places most research peptides in a gray zone while branded GLP-1 medicines remain legal by prescription.
Legal status overview
New York's peptide status is a gray zone defined by federal law rather than any state peptide statute. No New York statute, regulation, or Board of Pharmacy rule names peptides or research chemicals as a distinct legal category, so their status turns on general FDA drug law plus New York Education Law and pharmacy compounding rules. FDA-approved medicines such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal to prescribe and dispense, while unapproved peptides sold as research chemicals face federal unapproved-drug and misbranding enforcement. New York tends toward strict pharmacy oversight, and enforcement of unapproved peptides generally comes through federal FDA action.
Key points
- New York has no statute, regulation, or Board of Pharmacy rule that names peptides or research chemicals as a distinct legal category, so their legality is determined by federal FDA drug law plus New York's ordinary prescription-drug and compounding rules. [1]
- The New York State Board of Pharmacy, within the New York State Education Department's Office of the Professions, oversees pharmacy practice, and Education Law Part 63 sets sterile-compounding standards for injectable products rather than peptide-specific rules. [7]
- Federal law creates two compounding tracks that apply in New York: Section 503A patient-specific compounding by state-licensed pharmacies and Section 503B outsourcing facilities inspected by the FDA. [3]
- BPC-157 and TB-500 are not FDA-approved and have no USP monograph; the FDA placed a group of peptides in Category 2 of the 503A review as substances that may present significant safety risks, leaving these peptides in a gray zone in New York. [4]
- A Pharmacy Compounding Advisory Committee (PCAC) meeting backed adding several peptides to the 503A bulk drug substances list, but formal addition requires FDA notice-and-comment rulemaking that has not been finalized. [6]
- Compounded GLP-1 copies lost their broad legal pathway after the FDA declared the semaglutide and tirzepatide shortages resolved, ending enforcement discretion for 503A pharmacies on April 22, 2025 for semaglutide and February 2025 for tirzepatide, a federal action that controls in New York. [2]
- States including New York regulate above the federal floor, and the FDA has issued warning letters treating marketing claims for compounded semaglutide and tirzepatide as false or misleading under the federal Food, Drug, and Cosmetic Act. [5]
- Peptides sold as research use only or not for human consumption are not carved out by New York law and fall under the same federal unapproved-drug and misbranding framework the FDA enforces nationally. [8]
Compound-by-compound status
| BPC-157 Gray area | Not FDA-approved and not evaluated by the FDA for any disease. The FDA flagged it among peptides that may present significant safety risks in the 503A review, so a compounded BPC-157 product is not FDA-approved, not a generic, and not evaluated by the FDA. New York has no specific peptide law, leaving it a federal gray zone. |
|---|---|
| GLP-1 class (Wegovy® (semaglutide), Ozempic® (semaglutide), Mounjaro® (tirzepatide), Zepbound® (tirzepatide)) Restricted | Branded, FDA-approved GLP-1 medicines are legal to prescribe and dispense in New York. Compounded GLP-1 copies are largely restricted now that the FDA resolved the semaglutide and tirzepatide shortages and ended enforcement discretion; any compounded version is not FDA-approved, not a generic, and not evaluated by the FDA. |
| TB-500 (thymosin beta-4 fragment) Gray area | Not FDA-approved and not evaluated by the FDA. Reviewed by the FDA among peptides that may present significant safety risks and not added to the permitted 503A bulk list, so a compounded TB-500 product is not FDA-approved, not a generic, and not evaluated by the FDA. No New York statute names it, leaving it a gray zone. |
| Growth hormone peptides / somatropin (sermorelin, ipamorelin, CJC-1295) Restricted | FDA-approved somatropin is a prescription drug. Sermorelin has an approval history and can be compounded in some cases, while ipamorelin and CJC-1295 are not FDA-approved, not generics, and not evaluated by the FDA, and were subject to Category 2 compounding review. New York regulates growth hormone products through prescription and pharmacy rules. |
Frequently asked questions
Are peptides legal in New York?
There is no New York law that names peptides as a separate category, so legality depends on federal FDA rules and New York pharmacy law. FDA-approved peptide medicines are legal by prescription, while unapproved research peptides sit in a gray zone and can draw federal enforcement. This is information, not legal or medical advice.
Can a New York pharmacy compound BPC-157 or TB-500?
These peptides are not FDA-approved and were reviewed as substances that may present significant safety risks, so they are not on the permitted 503A bulk list. A compounded BPC-157 or TB-500 product is not FDA-approved, not a generic, and not evaluated by the FDA, which keeps compounding legally uncertain in New York.
Is compounded semaglutide or tirzepatide still allowed in New York?
Broad compounding of GLP-1 copies ended after the FDA resolved the shortages in early 2025. Branded, FDA-approved options such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) remain legal by prescription, while compounded copies are largely restricted and are not FDA-approved, not a generic, and not evaluated by the FDA.
Who regulates peptides in New York?
The New York State Board of Pharmacy within the New York State Education Department's Office of the Professions oversees pharmacy practice, the New York State Department of Health handles related health matters, and the FDA governs drug approval and compounding at the federal level.
Do research use only labels make peptides legal in New York?
No. A research use only or not for human consumption label does not exempt a product from federal drug law. If marketing points to human use, the FDA can treat the product as an unapproved or misbranded drug, and New York does not carve out these products.
Sources
- New York Peptide Laws & Regulations - PeptideLaws.com (retrieved 2026-09-21)
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize - FDA (retrieved 2026-09-21)
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act - FDA (retrieved 2026-09-21)
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - FDA (retrieved 2026-09-21)
- Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides - National Law Review (retrieved 2026-09-21)
- Bulk-list bound? PCAC backs majority of peptides in two-day public meeting - McDermott Will & Emery (retrieved 2026-09-21)
- Compounding Pharmacy New York: 2026 Regulatory Guide - Nationwide Compounding (retrieved 2026-09-21)
- Understanding Peptides: FDA-Approved vs. Research Chemicals - Healthline (retrieved 2026-09-21)
Last researched: 2026-09-21.